MetaVia Advances Obesity Drug DA-1726 with Dosing of 48 mg Cohort in Ongoing Phase 1 Trial

Top-line data expected by year-end as company evaluates maximum tolerated dose of novel GLP-1/glucagon receptor dual agonist

The clinical-stage biotechnology company focused on transforming cardiometabolic diseases MetaVia Inc. (Nasdaq: MTVA) has announced the initiation of the 48 mg multiple ascending dose (MAD) cohort in its ongoing Phase 1 clinical trial evaluating DA-1726, a dual oxyntomodulin (OXM) analog agonist designed to target both GLP-1 and glucagon receptors for the treatment of obesity. The first patient has been dosed in this highest cohort to date, with top-line results expected in the fourth quarter of 2025.

DA-1726 has already shown promise in earlier cohorts, including at the 32 mg dose, which delivered statistically significant, dose-dependent weight loss, early satiety in 83% of participants, and measurable reductions in waist circumference and fasting glucose, all without hypoglycemia or titration.

The dosing of the first patient in the 48 mg cohort marks the achievement of another key milestone for this promising cardiometabolic asset, said Hyung Heon Kim, President and CEO of MetaVia. The addition of a higher dose to the Phase 1 trial will help define the maximum tolerated dose and further unlock the full potential of DA-1726.

In previously reported results, DA-1726 produced a mean weight loss of 4.3% (max 6.3%) by Day 26, reduced waistlines by an average of 1.6 inches, and lowered fasting glucose by up to 18 mg/dL, all while maintaining a favorable cardiovascular safety profile. Notably, gastrointestinal side effects were mild, transient, and infrequent. This potentially sets DA-1726 apart from other GLP-1-based therapies, which often carry a high discontinuation rate.

Mr. Kim added, We continue to believe that DA-1726's 3:1 balanced activation of GLP-1 and glucagon receptors offers a promising alternative to current GLP-1 agonists, addressing significant tolerability challenges.

The randomized, double-blind, placebo-controlled Phase 1 study is assessing the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DA-1726 in otherwise healthy obese adults (BMI 30-45 kg/m(2)). Subjects are randomized 6:3 to receive either four weekly doses of DA-1726 or placebo, with primary endpoints focused on adverse events and safety. Secondary and exploratory endpoints include drug exposure, metabolic markers, cardiovascular metrics, and changes in body composition.

More information about the study is available at clinicaltrials.gov under the identifier NCT06252220.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.

This article contains sponsored content. Please see our disclaimer at: https://prismmarketview.com/disclaimer/

The post MetaVia Advances Obesity Drug DA-1726 with Dosing of 48 mg Cohort in Ongoing Phase 1 Trial appeared first on PRISM MarketView.

COMTEX_467164639/2927/2025-07-09T11:31:19